• Rezolute's Phase 3 sunRIZE trial of ersodetug missed its primary endpoint for reducing weekly hypoglycemia events in congenital hyperinsulinism.
• Continuous glucose monitoring showed clinically meaningful reductions, but time in hypoglycemia was not statistically significant at week 24.
• The FDA encouraged a pre-BLA meeting request; a biologics license application for congenital hyperinsulinism is targeted for 2027.
• Topline data from the tumor hyperinsulinism program are expected in December 2026.
• Cash of $108 million provides funding through the first quarter of 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.